S&P 500
5,921.54
+2.0%
+$118.72
DJI
42,343.65
+1.8%
+$740.58
NASDAQ
19,199.16
+2.5%
+$461.96
Bitcoin
109,873.00
+0.7%
+785.77
AAPL
$200.00
+2.4%
+$4.73
AMZN
$205.78
+2.4%
+$4.79
GOOG
$173.90
+2.5%
+$4.32
META
$641.62
+2.3%
+$14.56
MSFT
$460.09
+2.2%
+$9.91
NVDA
$135.32
+3.1%
+$4.03
TSLA
$361.87
+6.6%
+$22.53
Cyteir Therapeutics (NASDAQ: CYT)
Some price data may be temporarily unavailable.
Cyteir Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cyteir Therapeutics Company Info
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA.
News & Analysis
No articles found.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.